Pluristem Therapeutics Will Present the Phase I Study for PLX-PAD in Critical Limb Ischemia at MSC2009 Regenerative Medicine and Adult Stem Cell Therapy Conference
Business Wire
Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT) today announced that the Phase I study for PLX-PAD in critical limb ischemia (CLI) will be presented at the MSC2009 Regenerative Medicine and Adult Stem Cell Therapy conference.
William Prather R.Ph., M.D., Pluristem’s senior vice president corporate development, will present the study design in an oral presentation titled “Update on Pluristem's Phase I Clinical Trial Using PLX-PAD in Critical Limb Ischemia” at noon EDT, Wednesday, Aug. 19. Information on the Phase I study of PLX-PAD for CLI will also be available on a poster presentation. MSC2009 will be held on Aug. 17-19, 2009, at the Cleveland Marriott Downtown at Key Center, Cleveland, Ohio.
“This will be the first scientific forum where we will be informing our peers in the adult stem cell community on our Phase I dose escalating clinical studies using PLX-PAD,” said Zami Aberman, chairman, president and CEO of Pluristem. “This study is ongoing in Europe, enrolling patients diagnosed with critical limb ischemia, the end stage of peripheral artery disease.”
About MSC 2009
The Regenerative Medicine and Adult Stem Cell Therapy Conference (MSC2009) will be held on August 17-19, 2009 in Cleveland, Ohio (www.msc2009.net). MSC2009 will offer a forum for the exchange and discussion of research, ideas, and cutting-edge breakthroughs in translational regenerative medicine. The focus of the conference is on the isolation, characterization, purity, plasticity and clinical uses of adult stem cells from a variety of human and animal tissues including bone marrow, fat, cord blood and matrix, placenta and amniotic fluid.
About the National Center for Regenerative Medicine
The National Center for Regenerative Medicine (NCRM; www.ncrm.us) in Cleveland, OH, brings together over 120 researchers and physicians from Case Western Reserve University, the Cleveland Clinic and University Hospitals Case Medical Center. The NCRM provides a comprehensive approach, including basic through clinical as well as biomedical and tissue engineering research approaches, to develop new adult (non-embryonic) stem cell therapies for patients suffering from chronic and debilitating diseases including heart disease, cancer, genetic disorders, orthopedics, musculoskeletal and neurodegenerative diseases and injuries such as multiple sclerosis and spinal cord injury. |
